English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 907272      Online Users : 908
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/7733


    Title: Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
    Authors: Hsu, C;Tsou, HH;Lin, SJ;Wang, MC;Yao, M;Hwang, WL;Kao, WY;Chiu, CF;Lin, SF;Lin, J;Chang, CS;Tien, HF;Liu, TW;Chen, PJ;Cheng, AL
    Contributors: National Institute of Cancer Research;Division of Biostatistics and Bioinformatics
    Abstract: Fatal hepatitis B virus (HBV) reactivation in lymphoma patients with 'resolved' HBV infection (HBsAg-negative and anti-HBc-positive) has been reported but the true incidence and severity remain unclear. From June 2009 to December 2011, 150 newly diagnosed lymphoma patients with resolved HBV infection who were to receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-based chemotherapy were prospectively followed. HBV DNA was checked at baseline, at the start of each cycle of chemotherapy, and every 4 weeks for 1 year after completion of the rituximab-CHOP chemotherapy. Patients with documented HBV reactivation were treated with entecavir at a dosage of 0.5 mg/d for 48 weeks. HBV reactivation was defined as a greater than 10-fold increase in HBV DNA compared with previous nadir levels, and hepatitis flare was defined as a greater than 3-fold increase in ALT that exceeded 100 IU/L. The incidence of HBV reactivation and HBV-related hepatitis flares was 10.4 and 6.4 per person-year, respectively. Severe HBV-related hepatitis (ALT > 10 fold of upper normal limit) occurred in 4 patients despite entecavir treatment. Patients with hepatitis flare exhibited significantly higher incidence of re-appearance of HBsAg after HBV reactivation (100% vs. 28.5%; P=.003). Our data indicates that in lymphoma patients with resolved HBV infections, chemotherapy-induced HBV reactivation is not uncommon but can be managed with regular monitoring of HBV DNA and prompt antiviral therapy. Serological breakthrough (i.e., re-appearance of HBsAg) is the most important predictor of HBV-related hepatitis flare.
    Date: 2014-06
    Relation: Hepatology. 2014 Jun; 59(6):2092-2100
    Link to: http://dx.doi.org/10.1002/hep.26718
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0270-9139&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000337567100010
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84901591515
    Appears in Collections:[劉滄梧] 期刊論文
    [鄒小蕙] 期刊論文

    Files in This Item:

    File Description SizeFormat
    PUB24002804.pdf604KbAdobe PDF799View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback